{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:37:49Z","timestamp":1790678269453,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:p>\n            Large arteries from hypertensive subjects are hyperresponsiveness to 5-hydroxytryptamine (5-HT). We tested the hypothesis that small arteries (225 \u03bc ID) have a profile similar to conduit arteries, including signal transduction mechanisms and the 5-HT receptor subtype(s) mediating arterial contraction in normal and high blood pressure. Aorta and mesenteric arteries from Sprague-Dawley (232\u00b16 \u03bc ID), sham (229\u00b17 \u03bc ID; systolic blood pressure, 120\u00b12 mm Hg), or deoxycorticosterone acetate (DOCA)\u2013salt rats (255\u00b111 \u03bc ID, 192\u00b18 mm Hg) were mounted in a wire-based myograph. In resistance arteries from Sprague-Dawley rats, the 5-HT\n            <jats:sub>2A<\/jats:sub>\n            receptor mediated contraction; agonists of the 5-HT\n            <jats:sub>1B<\/jats:sub>\n            , 5-HT\n            <jats:sub>1D<\/jats:sub>\n            , 5-HT\n            <jats:sub>1F<\/jats:sub>\n            , and 5-HT\n            <jats:sub>2B<\/jats:sub>\n            receptor were inactive. The tyrosine kinase inhibitor genistein (5 \u03bcmol\/L, 4.8-fold rightward shift), PD 098,059 (10 \u03bcmol\/L, 3.2-fold shift), phospholipase C inhibitor NCDC (100 \u03bcmol\/L), and nifedipine (50 nmol\/L) reduced maximum 5-HT\u2013induced contraction in small arteries (4.5% and 53% control, respectively). As in aorta, 5-HT had a decrease in threshold (100-fold lower), increase in potency (11.6-fold leftward shift), and increase in efficacy (140% sham response) in small arteries from DOCA-salt rats compared with sham. Unlike in aorta, 5-HT\u2013induced contraction in DOCA-salt small arteries was shifted competitively by the 5-HT\n            <jats:sub>2A<\/jats:sub>\n            receptor antagonist ketanserin (\u2212log K\n            <jats:sub>B<\/jats:sub>\n            [mol\/L] for both sham and DOCA-salt, 9.25\u00b10.1), and contraction to the 5-HT\n            <jats:sub>2B<\/jats:sub>\n            agonist BW723C86 was not observed. Thus, the 5-HT\n            <jats:sub>2A<\/jats:sub>\n            receptor remains the contractile receptor in hypertension in small arteries. Although similarities were observed for large and small arteries, differences under the condition of DOCA-salt hypertension exist that may determine serotonergic compounds effective in lowering blood pressure.\n          <\/jats:p>","DOI":"10.1161\/hy0302.104668","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T23:16:47Z","timestamp":1027898207000},"page":"825-829","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Serotonin-Induced Contraction in Mesenteric Resistance Arteries"],"prefix":"10.1161","volume":"39","author":[{"given":"Stephanie W.","family":"Watts","sequence":"first","affiliation":[{"name":"From the Department of Pharmacology and Toxicology, Michigan State University, East Lansing."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1986.tb11150.x"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198500077-00014"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1970.219.3.687"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641969009074734"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.9.3.277"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.5.5.676"},{"key":"e_1_3_2_7_2","first-page":"35","volume":"38","year":"1991","unstructured":"Vanhoutte PM. Serotonin, hypertension and vascular disease. Neth J Med. 1991; 38: 35\u201342.","journal-title":"Neth J Med"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.11.2.111"},{"key":"e_1_3_2_9_2","first-page":"158","volume":"46","year":"1994","unstructured":"Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane WJ, Saxena PR, Humphrey PPA. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994; 46: 158\u2013203.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_2_10_2","first-page":"197","volume":"4","year":"1997","unstructured":"Watts SW. The 5-HT2B receptor antagonist LY272015 inhibits 5-HT\u2013induced contraction in the aorta of mineralocorticoid-salt hypertensive rats. J Ser Res. 1997; 4: 197\u2013206.","journal-title":"J Ser Res"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816060-00012"},{"key":"e_1_3_2_12_2","first-page":"1103","volume":"277","year":"1996","unstructured":"Watts SW, Baez M, Webb RC. The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate\u2013salt hypertension. J Pharmacol Exp Ther. 1996; 277: 1103\u20131113.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.6.1056"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1999.276.3.H944"},{"key":"e_1_3_2_15_2","first-page":"549","volume":"42","year":"1992","unstructured":"Kursar JD, Nelson DL, Wainscott DB, Cohen ML, Baez M. Molecular cloning, functional expression and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol. 1992; 42: 549\u2013557.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_16_2","first-page":"419","volume":"43","year":"1993","unstructured":"Wainscott D, Cohen ML, Schenck KW, Audia JE, Nissen JS, Baez M, Kursar JD, Lucaites VL, Nelson DL. Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993; 43: 419\u2013426.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_17_2","first-page":"487.","volume":"38","year":"2001","unstructured":"Banes AKL, Watts SW. Direct upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone actate\u2013salt hypertension by mineralocorticoids. Hypertension. 2001; 38: 487.","journal-title":"Hypertension"},{"key":"e_1_3_2_18_2","first-page":"480","volume":"238","year":"1986","unstructured":"Roth BL, Nakaki T, Chuang D-M, Costa E. 5-hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester. J Pharmacol Exp Ther. 1986; 238: 480\u2013485.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_19_2","first-page":"421","volume":"218","year":"1981","unstructured":"Cohen ML, Fuller RW, Wiley KS. Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle. J Pharmacol Exp Ther. 1981; 218: 421\u2013425.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006999031932"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(94)90048-5"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703081"},{"key":"e_1_3_2_23_2","first-page":"935","volume":"290","year":"1999","unstructured":"Cohen ML, Schenck K. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999; 290: 935\u2013939.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1999.276.3.H976"},{"key":"e_1_3_2_25_2","first-page":"233P.","volume":"123","year":"1998","unstructured":"Brown AM, Avenell K, Young TJ, Ho M, Porter RA, Vimal M, Middlemiss DN. BRL54443, a potent agonist with selectivity for human cloned 5-HT1E and 5-HT1F receptor. Br J Pharmacol. 1998; 123: 233P.","journal-title":"Br J Pharmacol"},{"key":"e_1_3_2_26_2","first-page":"88","volume":"297","year":"2001","unstructured":"McKune C, Watts SW. Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther. 2001; 297: 88\u201395.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_27_2","first-page":"598","volume":"294","year":"2000","unstructured":"Russell AR, Watts SW. Vascular reactivity of isolated thoracic aorta of the C57BL\/6J mouse. J Pharmacol Exp Ther. 2000; 294: 598\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00885-0"},{"key":"e_1_3_2_29_2","first-page":"1541","volume":"279","year":"1996","unstructured":"Watts SW. Serotonin activates the mitogen-activated protein kinase pathway in vascular smooth muscle: use of the mitogen-activated protein kinase kinase inhibitor PD098059. J Pharmacol Exp Ther. 1996; 279: 1541\u20131550.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_30_2","first-page":"346","volume":"284","year":"1998","unstructured":"Florian JA, Watts SW. Integration of mitogen activated protein kinase kinase activation in vascular 5-hydroxytryptamine2A receptor signal transduction. J Pharmacol Exp Ther. 1998; 284: 346\u2013355.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_31_2","first-page":"1179","volume":"291","year":"1999","unstructured":"Banes A, Florian JA, Watts SW. Mechanisms of 5-hydroxytryptamine2A receptor activation of the mitogen activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther. 1999; 291: 1179\u20131187.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_32_2","first-page":"617","volume":"269","year":"1994","unstructured":"Watts SW, Webb RC. Mechanism of ergonovine-induced contraction in the mesenteric artery from deoxycorticosterone acetate salt hypertensive rat. J Pharmacol Exp Ther. 1994; 269: 617\u2013625.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_33_2","unstructured":"Hoyer D. 5-Hydroxytryptamine receptors and effector coupling mechanism in peripheral tissues. In: Fozard JA ed. The Periphaeral Actions of 5-Hydroxytryptamine. Oxford: Oxford University Press; 1989: 72\u201399."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.38.4.891"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/hy0302.104668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T02:16:12Z","timestamp":1715652972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/hy0302.104668"}},"subtitle":["Signaling and Changes in Deoxycorticosterone Acetate\u2013Salt Hypertension"],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1161\/hy0302.104668"],"URL":"https:\/\/doi.org\/10.1161\/hy0302.104668","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]},"assertion":[{"value":"2001-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-12-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}